Page last updated: 2024-10-25

deferiprone and Bone Marrow Failure

deferiprone has been researched along with Bone Marrow Failure in 1 studies

Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.

Research Excerpts

ExcerptRelevanceReference
"Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event."7.83Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016)
"Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event."3.83Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belen, BF1
Polat, M1
Özsevik, SN1
Soylu, E1

Other Studies

1 other study available for deferiprone and Bone Marrow Failure

ArticleYear
Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy.
    Pediatric hematology and oncology, 2016, Volume: 33, Issue:1

    Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic; Blood Transfusion; Bone Marrow Diseases; Bone Marro

2016